Abstract 943: SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust antitumor efficacy and limited cross-resistance in ER+ breast cancer

帕博西利布 富维斯特朗 雌激素受体 癌症研究 药理学 三苯氧胺 雌激素受体α 医学 乳腺癌 癌症 内科学 转移性乳腺癌
作者
Monsif Bouaboula,Maysoun Shomali,Jane Cheng,Natalia V. Malkova,Fangxian Sun,Malvika Koundinya,Zhuyan Guo,Stephane Poirier,Mikhail Levit,Dietmar Hoffman,Hui Cao,Laurent Bestret,Francisco Adrián,C. Winter,Youssef El‐Ahmad,Sylvie Vincent,Frank Halley,Gary McCort,Laurent Schio,Vicky Richon
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:78 (13_Supplement): 943-943 被引量:10
标识
DOI:10.1158/1538-7445.am2018-943
摘要

Abstract Despite resistance to endocrine therapies, estrogen receptor-positive (ER+) breast cancers (BC) still rely on ER. Eliminating ER by inducing its degradation with selective ER downregulators (SERD) should induce complete ablation of ER pathways. The clinical SERD fulvestrant, although it has demonstrated clinical benefits, is hampered by its poor drug properties and undesirable pharmacokinetics, undermining its optimal clinical activity. Therefore there is an unmet need for an improved therapy targeting ER. Here we describe SAR439859, a novel, nonsteroidal, orally bioavailable SERD currently in clinical trials. SAR439859 has a potent ER antagonist and ER degrading activity that translates in a robust inhibition of ER signaling in multiple ER+ breast cancer cell lines, including tamoxifen-resistant lines as well as cell lines harboring ER mutations. SAR439859 displays a broad and superior ER degradation activity across a large panel of ER+ cells. Importantly, based on its mechanism of action SAR439859 shows limited cross-resistance with other clinical SERD molecules. SAR439859 induces strong in vivo antitumor activity against a variety of BC cell lines and patient-derived xenografts, including models that harbor ERα mutations. The transcriptional profile analysis highlighted a crosstalk of ER mutant signaling and other oncogenic pathways. Interestingly, CDK4/6 inhibition by palbociclib induces partial activation of ER pathways as potential mechanism of tumor escape, which is completely abolished by the combination of SAR439859 with palbociclib. Finally, we demonstrate that SAR439859 in combination with palbociclib can lead to higher in vivo efficacy. This study highlights novel mechanism of ER degradation by SAR439859 that leads to profound inhibition of ER signaling as well as modulation of other oncogenic pathways and provides rationale for the ongoing clinical investigation of SAR439859 in ER+ breast cancer patients, both as a single agent and in combination with approved agents, such as CDK4 inhibitor. Citation Format: Monsif Bouaboula, Maysoun Shomali, Jane Cheng, Natalia Malkova, Fangxian Sun, Malvika Koundinya, Zhuyan Guo, Stephane Poirier, Mikhail Levit, Dietmar Hoffman, Hui Cao, Laurent Bestret, Francisco Adrian, Christoph Winter, Youssef El-Ahmad, Sylvie Vincent, Frank Halley, Gary McCort, Laurent Schio, Vicky Richon, Hong Cheng, Karl Hsu, Chris Soria, Patrick Cohen, Joanne Lager, Carlos Garcia-Echeverria, Laurent Debussche. SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust antitumor efficacy and limited cross-resistance in ER+ breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 943.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
陈欣宜完成签到 ,获得积分10
1秒前
min20210429完成签到,获得积分10
1秒前
1秒前
子见南子完成签到,获得积分10
2秒前
opsliu完成签到,获得积分10
2秒前
西北射天狼完成签到,获得积分10
2秒前
Nizarn完成签到,获得积分10
3秒前
thinking完成签到,获得积分10
3秒前
伍wjm完成签到 ,获得积分10
3秒前
whatever完成签到,获得积分0
3秒前
3秒前
李翔完成签到,获得积分10
3秒前
3秒前
zy完成签到 ,获得积分10
4秒前
Hello的应助被wait采纳,获得10
4秒前
董晴完成签到,获得积分10
4秒前
zhou完成签到,获得积分20
4秒前
4秒前
相忘于江湖完成签到,获得积分10
4秒前
5秒前
松露完成签到,获得积分20
5秒前
5秒前
大海完成签到 ,获得积分10
6秒前
zzx完成签到,获得积分10
6秒前
Super_Tina发布了新的文献求助40
6秒前
清欢完成签到 ,获得积分10
6秒前
7秒前
Lvweieg完成签到,获得积分10
8秒前
英吉利25发布了新的文献求助10
8秒前
8秒前
8秒前
ryz99完成签到,获得积分10
9秒前
修哥发布了新的文献求助10
9秒前
zzy完成签到,获得积分10
9秒前
长风发布了新的文献求助10
9秒前
Joey完成签到 ,获得积分10
9秒前
团子呀完成签到 ,获得积分10
9秒前
iIl1oO0完成签到,获得积分10
10秒前
2024010070完成签到,获得积分10
10秒前
苹果小蜜蜂完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039